Oruka Therapeutics
ORKA
15 hedge funds and large institutions have $1.82M invested in Oruka Therapeutics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
103% more capital invested
Capital invested by funds: $898K → $1.82M (+$921K)
88% more funds holding
Funds holding: 8 → 15 (+7)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.58% → 0.58% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.69M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$107K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$82.1K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$61.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$59.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$258K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$138K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$71 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $1.27M | +$1.69M | +23,935 | +598,375% |
|
|
2
Renaissance Technologies
New York
| $169K | -$258K | -3,664 | -53% |
|
|
TCM
3
Tekla Capital Management
Boston,
Massachusetts
| $143K | – | – | – |
|
|
SSA
4
Schonfeld Strategic Advisors
New York
| $80K | +$107K | +1,517 | New |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $62K | +$82.1K | +1,164 | New |
|
|
SFI
6
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| $46K | +$61.2K | +868 | New |
|
|
7
Citadel Advisors
Miami,
Florida
| $45K | +$59.8K | +848 | New |
|
8
UBS Group
Zurich,
Switzerland
| $4K | +$5.43K | +77 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $1K | +$917 | +13 | New |
|
|
10
Acadian Asset Management
Boston,
Massachusetts
| – | -$138K | -1,742 | Closed |
|
|
11
Bank of America
Charlotte,
North Carolina
| – | -$71 | -1 | -25% |
|
|
KCM
12
Kathmere Capital Management
Wayne,
Pennsylvania
| – | +$141 | +2 | New |
|
13
Wells Fargo
San Francisco,
California
| – | +$141 | +2 | +200% |
|
|
QT
14
Quantbot Technologies
New York
| – | +$212 | +3 | New |
|
15
Osaic Holdings
Scottsdale,
Arizona
| – | +$564 | +8 | +160% |
|
ORKA Hedge Fund Activity: Q3 2020 in Review
15 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2020, worth a combined $1.82M — up 103% from $898K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ORKA positions and 1 closed out — a net gain of 7 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $1.69M. The largest seller was Renaissance Technologies, cutting an estimated $258K.
- 15 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2020, up from 8 in Q2 2020.
- Funds reported $1.82M of Oruka Therapeutics stock for Q3 2020, up 103% quarter-over-quarter.
- 8 funds opened new Oruka Therapeutics positions in Q3 2020 and 1 closed out, a net change of +7 holders.
- The largest Oruka Therapeutics buyer in Q3 2020 was BlackRock, an estimated $1.69M added.
- The largest Oruka Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $258K sold.
Based on aggregated 13F filings for Q3 2020.